PRO DEX INC(PDEX)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
PRO DEX INC (PDEX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PDEX at 62.2/100 on a 32-signal composite quality model, placing it at rank #728 of 2,961 stocks — the top 25% of the AI-ranked universe. PDEX scores in the top quartile across balance sheet strength (95.8), profitability (81.1), revenue growth (79.9). Areas of concern include revenue scale (12.6) and institutional flow (21.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), PRO DEX INC reports quarterly revenue of $20.4M, net income of $2.9M, an operating margin of 17.3%. Top institutional holders of PDEX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. PDEX trades on the Nasdaq exchange and files with the SEC under CIK 788920. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PDEX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRO DEX INC directly from SEC EDGAR.
AI Quality Score
62.2/100
AI Rank
#728
Revenue
$20.4M
Net Income
$2.9M
Free Cash Flow
$-476.0K
Operating Margin
17.3%
PDEX key financials by period
PRO DEX INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2026
10-K
$77.5M
$13.7M
16.8%
FY 2025
10-K
$66.6M
$9.0M
16.1%
FY 2024
10-K
$53.8M
$2.1M
13.3%
FY 2023
10-K
$46.1M
$7.1M
12.5%
FY 2022
10-K
$42.0M
$4.6M
12.2%
FY 2021
10-K
$38.0M
$6.2M
11.9%
Institutions holding PDEX
Institutional investors reporting a position in PRO DEX INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-04-30 — Q3 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net sales rose 15% YoY to $19.9M on a 36% jump in medical device sales tied to the largest customer's contract extension, while repair revenue fell 48% as that customer shifts to next-gen handpieces.
Biggest Revenue Drivers
Medical device products$16.2M+36% YoY
Increase driven by higher orthopedic sales to largest customer following contract extension through 2028
Repairs$2.7M-48% YoY
Fewer repairs of the legacy orthopedic handpiece sold to largest customer
Biggest Revenue Drivers
Total revenue: $19.9M+15% YoY
Medical device products$16.2M+36% YoY
Increase driven by higher orthopedic sales to largest customer following contract extension through 2028
Within Medical device products
Orthopedic$13.1M+$4.5M YoY
Largest customer's medical device revenue increased on contract amendment extending supply through 2028
Repairs$2.7M-48% YoY
Fewer repairs of the legacy orthopedic handpiece sold to largest customer
NRE & Prototype$531K+186% YoY
Increase in billable contracts for various NRE projects undertaken for customers
Industrial and scientific$472K+78% YoY
Primarily due to inclusion of newly acquired APM sales since the February 9, 2026 acquisition date
Largest Expense Items
Cost of sales$13.8M+19% YoY
Consistent with 15% revenue increase; under-absorption of manufacturing costs rose $398K
General and administrative expenses$2.2M+98% YoY
Higher personnel costs, $233K of APM G&A, $250K consulting fees to APM's seller, and a $225K CEO bonus accrual
Research and development costs$827K-13% YoY
More project costs reclassified to cost of sales and reduced intellectual property legal costs
Margins: Gross margin fell 2 points YoY to 31% due to unfavorable product mix and higher manufacturing cost under-absorption, even though gross profit grew 6% on higher medical device revenue.
Watch Items from the Filing
Customer 1 represented 79% of net sales ($15.65M) and 75% of gross accounts receivable in the quarter, up from 77% a year ago.
Backlog stood at approximately $39.0M, with $15.6M scheduled for delivery in Q4 FY2026, supported by the customer contract extension through 2028.
Company took on new debt to fund the $8.65M APM acquisition: a $6.65M UMB Term Loan D plus a $2.0M subordinated note at 8% interest.
Quarter's income included a non-operating $2.3M gain from a Monogram/Zimmer Biomet contingent value right milestone, not from core operations.
Three suppliers accounted for 38% of inventory purchases in the quarter, with Supplier 1 alone at 21%.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
